NASDAQ · HKPD
Cellyan Biotechnology Co. financials
$0.1103+0.27%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY26 Mar 31 | FY25 Mar 31 |
|---|---|---|
| Revenue | $13.4M | $20.3M |
| Gross profit | $1.4M | $2.4M |
| Gross margin | 10.3% | 11.9% |
| Operating income | -$1.0M | $199.3K |
| Net income | -$1.1M | -$27.1K |
| Net margin | −8.5% | −0.1% |
| Diluted EPS | $-0.07 | $0.00 |
| EBITDA | -$922.2K | $275.1K |
| Operating cash flow | -$751.6K | $569.2K |
| Free cash flow | -$787.1K | $499.3K |
| Diluted shares | 16.3M | 10.2M |
Balance sheet
| Period end | Mar 31 | Mar 31 |
|---|---|---|
| Cash & equivalents | $221.8K | $748.7K |
| Short-term investments | $0.00 | $2.3M |
| Total debt | $877.9K | $1.9M |
| Total assets | $12.8M | $9.4M |
| Total liabilities | $3.3M | $4.4M |
| Shareholders' equity | $9.6M | $5.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology